Urinary tract infections (UTIs) refer to a common bacterial infection disease, that occurs in either a community or healthcare setting. Typical symptoms of UTIs include fever, chills, malaise, flank pain, back pain, and/or costo-vertebral angle pain or tenderness, that occur in the presence of a functional or anatomical abnormality of the urinary tract or in the presence of catheterization.
UTIs THERAPEUTICS UNDER DEVELOPMENT (2018)
UTIs are caused by both gram-negative and gram-positive bacteria, as well as by certain fungi. UTIs is categorized as uncomplicated and complicated and the most common causative agent for both uncomplicated and complicated UTIs are uropathogenic Escherichia coli. The uncomplicated UTIs can also be caused by a broad range of pathogens such as Proteus mirabilis, Pseudomonas aeruginosa, Klebsiella pneumoniae, Staphylococcus saprophyticus, Staphylococcus aureus and others.
Further, the late stage drug candidates in the UTIs pipeline have been showing positive clinical results. For instance, ZOLYD, a drug candidate being developed by Zavante Therapeutics Inc., met the primary endpoint of statistical non-inferiority compared to piperacillin/tazobactam, with an overall success rate of 64.7%. Additionally, the pipeline is also characterized by increasing research and development activities, and licensing agreements among companies, educational institutes, and health organizations.
As of February 2018, the UTIs therapeutics pipeline comprises of 40 drug candidates in different stages of development.
Some of the key players involved in the development of UTIs therapeutics include Achaogen Inc., AmpliPhi Biosciences Corporation, and Iterum Therapeutics Limited.